Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.50 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.43 |
| ▸ | DHFR | P00374 | 2/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | C1S | P09871 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14827772 | 0.86 | RPS6KB1 (0.49) | MAPTRPS6KB1ADRB1KCNH2ALDH1A1 | |
| SCHEMBL9982465 | 0.79 | MAPT (0.55) | MAPTRPS6KB1GAAALDH1A1RAB9A | |
| SCHEMBL3874069 | 0.75 | KDM4E (0.64) | MAPTKDM4EGAAHDAC1HDAC8 | |
| SCHEMBL9982909 | 0.75 | GAA (0.43) | MAPTRPS6KB1KDM4EGAAALDH1A1 | |
| SCHEMBL9982790 | 0.74 | ADRB1 (0.59) | MAPTADRB1KCNH2ALDH1A1RAB9A | |
| SCHEMBL6629804 | 0.73 | NPY5R (0.57) | RPS6KB1GAAADRB1ALDH1A1RAB9A | |
| SCHEMBL720368 | 0.73 | MAPT (0.81) | MAPTKDM4EGAAALDH1A1MEN1 | |
| SCHEMBL30657522 | 0.73 | MAPT (0.81) | MAPTKDM4EGAAALDH1A1MEN1 | |
| SCHEMBL8054516 | 0.72 | ADRB1 (0.61) | MAPTADRB1KCNH2ALDH1A1RAB9A | |
| SCHEMBL3632946 | 0.72 | GAA (0.58) | MAPTKDM4EGAAKCNH2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2582681-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | Novartis AG (CH) | 2013-04-24 | — | — | EP | disclosed |
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2013-04-04 | — | — | US | disclosed |
| WO-2011157793-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
| WO-2011157793-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | NOVARTIS AG (CH) | 2011-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085161-A1 | PIPERIDINYL SUBSTITUTED 1,3-DIHYDRO-BENZOIMIDAZOL-2-YLIDENEAMINE DERIVATIVES | IGF1R, IGFBP1, IGFBP2 | MAPT 3004/4885RPS6KB1 124/4885KDM4E 2344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.